Diabetes, Vol 48, Issue 6 1289-1294, Copyright © 1999 by American Diabetes Association

ARTICLES

Effects of aggressive cholesterol lowering and low-dose anticoagulation on clinical and angiographic outcomes in patients with diabetes: the Post Coronary Artery Bypass Graft Trial

BJ Hoogwerf, A Waness, M Cressman, J Canner, L Campeau, M Domanski, N Geller, A Herd, A Hickey, DB Hunninghake, GL Knatterud and C White
Cleveland Clinic Foundation, OH 44195, USA. hoogweb@cesmtp.ccf.org

Diabetic patients have greater risk for coronary heart disease (CHD) events after coronary artery bypass graft (CABG) surgery than nondiabetic patients. The Post CABG trial studied the effects of aggressive cholesterol lowering and low-dose anticoagulation in diabetic patients compared with nondiabetic patients. A double-blind, randomized clinical trial in 1,351 patients (1-11 years after CABG), the Post CABG trial consisted of two interventions (aggressive cholesterol-lowering versus moderate lowering and low-dose warfarin versus placebo) on angiographic end points. Angiographic changes in saphenous vein graft conduits 4.3 years after entry were compared in 116 diabetic and 1,235 nondiabetic patients. Seven clinical centers participated in the trial, as well as the National Institutes of Health project office (National Heart, Lung, and Blood Institute), the coordinating center (Maryland Medical Research Institute), and the Angiogram Reading Center (University of Minnesota). Baseline characteristics of the diabetic patients differed from the nondiabetic patients in the following ways: percentage of women participants, 15 vs. 7%, P = 0.002; mean baseline weight, 87.4 vs. 82.8 kg, P = 0.006; mean BMI, 29.5 vs. 27.6 kg/m2, P = 0.0002; mean systolic blood pressure, 141.7 vs. 133.6, P < 0.0001; mean triglyceride concentrations, 2.09 vs. 1.77 mmol/l, P < 0.0001; and mean HDL cholesterol concentrations, 0.93 vs. 1.02 mmol, P = 0.0001. The percentage of clinical events was higher in diabetic than nondiabetic patients (20.6 vs. 13.4, P = 0.033) and angiographic outcomes were not different. The benefits of aggressive cholesterol lowering were comparable in diabetic and nondiabetic patients for the angiographic end points. Warfarin use was not associated with clinical or angiographic benefit. Diabetic patients in the Post CABG trial had more CHD risk factors at study entry and higher clinical event rates during the study than nondiabetic patients. The benefits of aggressive cholesterol lowering in diabetic patients were comparable to those in nondiabetic patients for both angiographic and clinical end points. The small number of diabetic patients provided limited power to detect significant differences between diabetic and nondiabetic patients or between diabetic patients in the aggressive versus moderate cholesterol treatment strategies.
CiteULike    Del.icio.us    Digg    Reddit    Technorati    What's this?

This article has been cited by other articles:

				B. V. Howard, M. J. Roman, R. B. Devereux, J. L. Fleg, J. M. Galloway, J. A. Henderson, Wm. J. Howard, E. T. Lee, M. Mete, B. Poolaw, et al. Effect of Lower Targets for Blood Pressure and LDL Cholesterol on Atherosclerosis in Diabetes: The SANDS Randomized Trial JAMA, April 9, 2008; 299(14): 1678 - 1689. [Abstract] [Full Text] [PDF]

				S. Mohammadi, F. Dagenais, P. Mathieu, J. G. Kingma, D. Doyle, S. Lopez, R. Baillot, J. Perron, E. Charbonneau, E. Dumont, et al. Long-Term Impact of Diabetes and Its Comorbidities in Patients Undergoing Isolated Primary Coronary Artery Bypass Graft Surgery Circulation, September 11, 2007; 116(11_suppl): I-220 - I-225. [Abstract] [Full Text] [PDF]

				M. E. Molitch Management of Dyslipidemias in Patients with Diabetes and Chronic Kidney Disease Clin. J. Am. Soc. Nephrol., September 1, 2006; 1(5): 1090 - 1099. [Abstract] [Full Text] [PDF]

				V. Snow, M. D. Aronson, E. R. Hornbake, C. Mottur-Pilson, K. B. Weiss, and the Clinical Efficacy Assessment Subcommittee of t Lipid Control in the Management of Type 2 Diabetes Mellitus: A Clinical Practice Guideline from the American College of Physicians Ann Intern Med, April 20, 2004; 140(8): 644 - 649. [Abstract] [Full Text] [PDF]

				S. Vijan and R. A. Hayward Pharmacologic Lipid-Lowering Therapy in Type 2 Diabetes Mellitus: Background Paper for the American College of Physicians Ann Intern Med, April 20, 2004; 140(8): 650 - 658. [Abstract] [Full Text] [PDF]

				L. M. Prisant Clinical Trials and Lipid Guidelines for Type II Diabetes J. Clin. Pharmacol., April 1, 2004; 44(4): 423 - 430. [Abstract] [Full Text] [PDF]

				R. Lorusso, S. Pentiricci, R. Raddino, T. M. Scarabelli, C. Zambelli, V. Villanacci, A. Burattin, G. Romanelli, S. Casari, R. Scelsi, et al. Influence of Type 2 Diabetes on Functional and Structural Properties of Coronary Artery Bypass Conduits Diabetes, November 1, 2003; 52(11): 2814 - 2820. [Abstract] [Full Text] [PDF]

				M. E. Charlson and O. W. Isom Care after Coronary-Artery Bypass Surgery N. Engl. J. Med., April 10, 2003; 348(15): 1456 - 1463. [Full Text] [PDF]

				M. Laakso and J. Kuusisto Diabetology for cardiologists Eur. Heart J. Suppl., January 1, 2003; 5(suppl_B): B5 - B13. [Abstract] [PDF]

				References Circulation, December 17, 2002; 106(25): 3373 - 3421. [Full Text]

				S. M. Haffner and R. B. Goldberg New Strategies for the Treatment of Diabetic Dyslipidemia Diabetes Care, July 1, 2002; 25(7): 1237 - 1239. [Full Text] [PDF]

				B. Huang, T. Dreyer, M. Heidt, J. C.M. Yu, M. Philipp, F. W. Hehrlein, N. Katz, and N. Al-Fakhri Insulin and local growth factor PDGF induce intimal hyperplasia in bypass graft culture models of saphenous vein and internal mammary artery Eur. J. Cardiothorac. Surg., June 1, 2002; 21(6): 1002 - 1008. [Abstract] [Full Text] [PDF]

				C. W. White, F. L. Gobel, L. Campeau, G. L. Knatterud, S. A. Forman, J. S. Forrester, N. L. Geller, J. A. Herd, A. Hickey, B. J. Hoogwerf, et al. Effect of an Aggressive Lipid-Lowering Strategy on Progression of Atherosclerosis in the Left Main Coronary Artery From Patients in the Post Coronary Artery Bypass Graft Trial Circulation, November 27, 2001; 104(22): 2660 - 2665. [Abstract] [Full Text] [PDF]

				D. L. Sprecher and G. L. Pearce How deadly is the "deadly quartet"?: A post-CABG evaluation J. Am. Coll. Cardiol., October 1, 2000; 36(4): 1159 - 1165. [Abstract] [Full Text] [PDF]